Biogen Targets GSK's Cancer Drug Arzerra In IP Suit

Law360, New York (March 25, 2010, 1:30 PM EDT) -- Biogen Idec Inc. and Genentech Inc. have sued GlaxoSmithKline LLC, claiming the British pharmaceutical company's cancer treatment Arzerra infringes their newly issued patent for an antibody treatment for leukemia.

The plaintiffs filed suit Tuesday in the U.S. District Court for the Southern District of California, seeking a declaration that GSK's manufacture and sale of ofatumumab violates U.S. Patent Number 7,682,612, titled “Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody.”

The U.S. Patent and Trademark Office issued the '612 patent Tuesday, assigning...
To view the full article, register now.